http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-044294-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D451-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D451-14 |
| filingDate | 2004-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-044294-A1 |
| titleOfInvention | N-ARILSULPHONYLPIPERIDINS LINKED AS INHIBITORS OF THE GAMMA-SECRETASE |
| abstract | Compound and pharmaceutical composition useful for Alzheimer's. Claim 1: A compound, or pharmaceutically acceptable salts and / or solvates of said compound, having the general structure illustrated in formula (1) in which: Ar is aryl or heteroaryl; X is O, NH or NR6; m is 0, 1, 2 or 3, provided that when m = 0, there is no double link present and when m> 0, there may or may not be a double link present or there may or may not be a triple link present; n is 0, 1, 2 or 3; R1 represents 1 to 3 substituents independently selected from the group consisting of H, alkyl, cycloalkyl, halogen, -CF3, -OCF3, -NR6R7, -CN, -NO2, -NH2, -alkylene-NR6R7, -alkylene-O- alkyl, -C (O) O-alkyl, -C (O) NR6R7, -N (R6) C (O) alkyl, - N (R6) C (O) cycloalkyl, -N (R6) C (O) aryl , -N (R6) C (O) heteroaryl, -N (R6) C (O) O-alkyl, -N (R6) C (O) NR6R7, -N (R6) S (O) 2alkyl, -OH, -O-alkyl and -O-cycloalkyl; R 2 is H, -alkyl, -cycloalkyl, -alkylene-cycloalkyl, -cycloalkyl, -NR6R7, -alkylene-NR6R7, -alkylene-O-alkyl, -O-alkyl, -heteroaryl or -aryl; R3 represents 1 to 6 substituents, which may be the same or different, each of which is selected from the group consisting of H, halogen, -alkyl, -cycloalkyl, -OH, - OCF3, -CF3, -O-alkyl , -O-cycloalkyl, or NR6R7; R4 is H, -alkyl, -cycloalkyl, -aryl or -heteroaryl; or R3 and R4 can be joined to form a 3 to 6 member ring; R5 is -NR6R7, -N (R6) -alkylene-NR6R7, -alkyl, -cycloalkyl, -aryl, - heteroaryl, -cycloalkyl, -alkylene-aryl, -alkylene-heteroaryl, -cycloalkylene-aryl, -cycloalkylene-heteroaryl, -heterocycloalkyl-aryl or -heterocycloalkyl-heteroaryl; or R5 is selected from the group consisting of formulas (2), R6 and R7 can be the same or different, and each of them is selected from the group consisting of H, -aryl, -heteroaryl, -alkyl, -cycloalkyl, -alkylene-aryl, -alkylene-heteroaryl, or with one of the compounds of formulas (3); r is 0, 1, 2, 3 or 4; s is 0, 1, 2, or 3; R6 is H, -OH, -alkyl, -C (O) NR6R7, -C (O) O-alkyl or aryl, wherein said alkyl portion may be unsubstituted or substituted with 1 to 4 hydroxy groups, and said aryl group may be unsubstituted or substituted with at least one substituent selected from the group consisting of alkyl, cycloalkyl, halogen, -CF3, -OCF3, -NR6R7, -CN, -NO2, -NH2, -alkylene-NR6R7, -alkylene- O-alkyl, -C (O) O-alkyl, -C (O) NR6R7, - N (R6) C (O) alkyl, -N (R6) C (O) cycloalkyl, -N (R6) C (O ) aryl, -N (R6) C (O) heteroaryl, -N (R6) C (O) O-alkyl, -N (R6) C (O) NR6R7, -N (R6) S (O) 2alkyl, - OH, -O-alkyl and -O-cycloalkyl; R9 is selected from the group consisting of H, -alkyl, -cycloalkyl, -alkylene-aryl, -alkylene-heteroaryl, -alkyl-cycloalkyl, C (O) O-alkyl, alkylene-O-alkylene-OH, -aryl and -heteroaryl, where each of said alkyl and cycloalkyl moieties may be independently substituted or unsubstituted and, if substituted, may be substituted with 1 to 4 hydroxy groups or at least one -NR6R7 group; each R10 is independently selected from H or alkyl, wherein said alkyl group may be substituted or unsubstituted and, if substituted, then R10 is substituted with 1 to 4 hydroxy groups; each R11 and R12 is independently selected from H, alkyl or aryl; or R11 and R12, together with the C atoms of the ring to which they appear attached in the formula (1), form a cycloalkyl ring and where the cycloalkyl ring thus formed may be unsubstituted or substituted with an alkyl, alkoxy, aryl or halogen; p is 0, 1, 2, 3 or 4 and q is 0, 1, or 2. |
| priorityDate | 2003-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.